Evidence map›Paper›PMID 31309302›Full record

ArticleJournal of cancer research and clinical oncology2019

Selective radiofrequency ablation of tumor by magnetically targeting of multifunctional iron oxide-gold nanohybrid.

Jaber Beyk, Hassan Tavakoli

Abstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jaber BeykNeuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-3953-5582
Hassan TavakoliNeuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. tavakoli@bmsu.ac.ir.

Funding

Baqiyatallah University of Medical Sciences 7970
6 · The paper itself

Abstract

purposeRadiofrequency (RF) ablation therapy is of great interest in cancer therapy as it is non-ionizing radiation and can effectively penetrate into the tissue. However, the current RF ablation technique is invasive that requires RF probe insertion into the tissue and generates a non-specific heating. Recently, RF-responsive nanomaterials such as gold nanoparticles (AuNPs) and iron oxide nanoparticles (IONPs) have led to tremendous progress in this area. They have been found to be able to absorb the RF field and induce a localized heating within the target, thereby affording a non-invasive and tumor-specific RF ablation strategy. In the present study, for the first time, we used a hybrid core-shell nanostructure comprising IONPs as the core and AuNPs as the shell (IO@Au) for targeted RF ablation therapy. Due to the magnetic core, the nanohybrid can be directed toward the tumor through a magnet. Moreover, IONPs enable the nanohybrid to be used as a magnetic resonance imaging (MRI) contrast agent.

resultsIn vitro cytotoxicity experiment showed that the combination of IO@Au and 13.56-MHz RF field significantly reduced the viability of cancer cells. Next, during an in vivo experiment, we demonstrated that magnetically targeting of IO@Au to the tumor and subsequent RF exposure dramatically suppressed the tumor growth.

conclusionTherefore, the integration of targeting, imaging, and therapeutic performances into IO@Au nanohybrid could afford the promise to improve the effectiveness of RF ablation therapy.

Indexed as

AnimalsCatheter AblationFerric CompoundsGoldHyperthermia, InducedMagnetic Resonance ImagingMagnetite NanoparticlesMaleMetal NanoparticlesMiceMice, Inbred BALB CMolecular Targeted TherapyNanocompositesNanoshellsNeoplasmsRadiofrequency AblationFerric Compoundsferric oxideGoldMagnetite NanoparticlesGold nanoparticlesIron oxide nanoparticlesMagnetic resonance imagingMagnetic targetingRadiofrequency ablation

Identifiers

PMID31309302
PMCPMC11810371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.